Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
- Posted on February 3, 2026
- By CNBC
- 4 Views
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.
